Amundi Purchases 33,522 Shares of Bruker Corporation $BRKR

Key Points

• Amundi increased its stake in Bruker Corporation by 373.3% during the 1st quarter, raising its holdings to 42,503 shares worth approximately $1.77 million.
• Bruker announced a quarterly dividend of $0.05 per share, set to be paid on October 3rd, providing a yield of 0.6%.
• An earnings report revealed that Bruker missed analyst expectations, reporting an EPS of $0.32 and revenues of $797.4 million in the last quarter, with FY 2025 guidance set between $1.950 - $2.050 EPS.

Amundi grew its stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 373.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 42,503 shares of the medical research company's stock after buying an additional 33,522 shares during the quarter. Amundi's holdings in Bruker were worth $1,774,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pinnacle Bancorp Inc. purchased a new stake in shares of Bruker in the 1st quarter worth about $29,000. Allworth Financial LP lifted its position in shares of Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock worth $30,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock worth $33,000 after purchasing an additional 745 shares during the period. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Bruker in the 1st quarter worth about $42,000. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of Bruker by 274.9% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock worth $46,000 after purchasing an additional 800 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Price Performance

NASDAQ:BRKR traded up $1.16 during trading hours on Thursday, hitting $33.27. 4,160,895 shares of the stock traded hands, compared to its average volume of 4,546,535. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $72.94. The company has a market cap of $5.05 billion, a price-to-earnings ratio of 63.98, a price-to-earnings-growth ratio of 4.46 and a beta of 1.21. The stock has a 50 day moving average price of $35.25 and a 200 day moving average price of $38.55.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $797.40 million for the quarter, compared to analysts' expectations of $811.17 million. During the same period in the prior year, the firm earned $0.52 EPS. Bruker's revenue for the quarter was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Sell-side analysts forecast that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker's payout ratio is 38.46%.

Insider Activity at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the business's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the transaction, the director owned 18,016 shares of the company's stock, valued at approximately $581,016. The trade was a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 27.30% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BRKR. Citigroup decreased their target price on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, August 4th. Barclays decreased their target price on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Monday, August 4th. Wells Fargo & Company decreased their target price on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a report on Tuesday, August 5th. Bank of America decreased their target price on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Finally, Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the stock a "buy" rating in a report on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $51.30.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.